Related Experiment Videos
Percutaneous transluminal septal myocardial ablation
D N Rubin1, E M Tuzcu, H M Lever
1Department of Cardiology, Desk F-15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Current Cardiology Reports
|September 12, 2000
Summary
Percutaneous transluminal septal myocardial ablation (PTSMA) offers a minimally invasive treatment for hypertrophic obstructive cardiomyopathy. This catheter-based procedure provides symptomatic relief and reduces outflow tract obstruction in most patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Device Technology
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) presents significant symptoms and is refractory to medical management.
- Current treatment options like surgical myectomy carry substantial risks, especially for patients with comorbidities.
Purpose of the Study:
- To evaluate the efficacy and safety of percutaneous transluminal septal myocardial ablation (PTSMA) as an investigational treatment for HOCM.
- To assess the impact of PTSMA on symptoms, outflow tract obstruction, and exercise capacity.
Main Methods:
- PTSMA involves catheter-based cannulation of septal perforator arteries.
- Ethyl alcohol injection induces targeted septal infarction to relieve obstruction.
- Myocardial contrast echocardiography monitors the procedure and infarct extent.
Main Results:
- PTSMA leads to septal scarring and thinning over 6-12 weeks.
- Most patients experience symptomatic improvement and reduced outflow tract gradients.
- A common complication is high-grade atrioventricular block requiring pacemaker implantation in 25% of patients.
Conclusions:
- PTSMA is a promising, minimally invasive alternative to surgical myectomy for HOCM.
- The procedure demonstrates favorable risk profile, especially for comorbid patients.
- International registries are crucial for further assessing PTSMA's long-term success and safety.